149 BIO LLC
Small molecule allosteric agonists of integrin CD11b (LA1 and analogs) for treating lupus nephritis
- Sector
- Biotech
- Headquarters
- Miami, FL
- Total capital
- $613K
- Federal grants
- $613K
- 2 awards · 2023
- Rank in peer group#479 of 502
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 6 pending · first 2025
- Rank in peer group#57 of 502
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Integrin-Targeted Novel Oral Therapeutics for Lupus Nephritis$307K
- Federal grantHealth and Human S · Phase I · Integrin-Targeted Novel Oral Therapeutics for Lupus Nephritis$307K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 502 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#57 · top 11%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 1 granted of 7- PendingCD11B Agonists For Treatment Of Autoimmune DiseaseUSPTOApplication 19120990
- GrantedReagents and Assays using Modified Integrin DomainsUSPTOUS 12,291,562
- PendingCD11B Agonists For Treatment Of Autoimmune DiseaseUSPTOApplication PCTUS2023035247
Show all 7 patent records
- CD11B Agonists For Treatment Of Autoimmune DiseaseMay 21, 2026 · Application 19120990Pending
- Reagents and Assays using Modified Integrin DomainsMay 6, 2025 · US 12,291,562Granted
- CD11B Agonists For Treatment Of Autoimmune DiseaseApplication PCTUS2023035247Pending
- CD11B Agonists For Treatment Of Autoimmune DiseaseApplication 63416436Pending
- Reagents And Assays Using Modified Integrin DomainsApplication PCTUS2020025898Pending
- Compositions And Methods Involving Integrin ALPHA3BETA1Application 63420964Pending
- Compositions And Methods Involving Integrin ALPHA3BETA1Application PCTUS2023078109Pending
Related companies, and why
- DOLOR THERAPEUTICS, LLCSimilar federal contract value in Biotech · null in contracts
- DELUGE BIOTECHNOLOGIES INCSimilar federal contract value in Biotech · null in contracts
- MAJESTIC THERAPEUTICS, LLCSimilar federal contract value in Biotech · null in contracts
- ECHELON BIOSCIENCES, INC.Similar federal contract value in Biotech · null in contracts
- Dignify Therapeutics LLCSimilar federal contract value in Biotech · null in contracts
- NORTHSTAR GENOMICS, LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .